Unveiling the potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in offering protection of the cardiovascular, renal, and neural systems: an updated narrative review
NHS Guidance on GLP-1 Agonist Treatment Options NICE guidance provides the framework for GLP-1 agonist prescribing within the NHS, balancing clinical effectiveness with cost-effectiveness considerations
Any episode of syncope (loss of consciousness) requires immediate medical assessment, as this may indicate significant hypotension or other serious conditions requiring investigation
Delve deep with Bolt Pharmacy as we challenge the question "Does Wegovy Cause Diverticulitis?" Join us as we unravel the correlations, causes, and precautions associated with this GLP-1 medication, providing you with trustworthy insights to support your health journey
More states may cover GLP-1s for weight loss in 2026 through the new CMS BALANCE Model, which launches for Medicaid as early as May 2026
GLP-1 drugs are not recommended for people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B
